Analytical Data
-
基因名
GALM
- Application
-
别名
GALM;Galactose mutarotase
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q96C23
-
表达区间
1-342aa
-
氨基酸序列
MGSSHHHHHHSSGLVPRGSHMASVTRAVFGELPSGGGTVEKFQLQSDLLR VDIISWGCTITALEVKDRQGRASDVVLGFAELEGYLQKQPYFGAVIGRVA NRIAKGTFKVDGKEYHLAINKEPNSLHGGVRGFDKVLWTPRVLSNGVQFS RISPDGEEGYPGELKVWVTYTLDGGELIVNYRAQASQATPVNLTNHSYFN LAGQASPNINDHEVTIEADTYLPVDETLIPTGEVAPVQGTAFDLRKPVEL GKHLQDFHLNGFDHNFCLKGSKEKHFCARVHHAASGRVLEVYTTQPGVQF YTGNFLDGTLKGKNGAVYPKHSGFCLETQNWPDAVNQPRFPPVLLRPGEE YDHTTWFKFSVA
-
分子量
40 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GALM (Galactose-1-phosphate uridylyltransferase and galactose-4-epimerase) is an essential enzyme complex involved in the metabolism of galactose, specifically in the conversion of galactose-1-phosphate to UDP-galactose. Congenital disorders of galactose metabolism, particularly galactosemia, arise from deficiencies in these enzymes, leading to severe clinical manifestations such as liver damage, kidney complications, and neurological impairment if left untreated. Research on GALM recombinant proteins has gained traction as scientists seek to understand the structure-function relationships and regulatory mechanisms involved in its enzymatic activity. These studies provide insights into critical aspects of galactose metabolism and potential therapeutic strategies for managing metabolic disorders related to galactose. Advances in techniques such as protein engineering and structural biology enable researchers to produce and characterize GALM variants, facilitating a deeper understanding of its role in metabolic pathways and offering new avenues for enzyme replacement therapies. By elucidating the molecular intricacies of GALM, researchers aim to pave the way for innovative treatments and interventions to improve the quality of life for individuals affected by galactose-related metabolic disorders.
